Guggenheim's Rating of Phathom Pharmaceuticals on 2/27/2026

On February 27, 2026, Guggenheim updated its outlook on Phathom Pharmaceuticals (NASDAQ:PHAT) with the action "Boost Price Target", setting a price target of $25.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Guggenheim

DateCompanyAction
11/20/2026
Tesla, Inc. stock logo
TSLA
Tesla
Upgrade
11/20/2026
Warner Music Group Corp. stock logo
WMG
Warner Music Group
Boost Price Target
11/20/2026
Woodward, Inc. stock logo
WWD
Woodward
Boost Price Target
11/20/2026
Centrus Energy Corp. stock logo
LEU
Centrus Energy
Boost Price Target
11/20/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Initiated Coverage
11/20/2026
X-Energy, Inc. stock logo
XE
X-Energy
Lower Price Target
More Ratings From Guggenheim